文献速递消化内镜

胰高血糖素样肽-1受体激动剂不增加糖尿病患者上消化道内镜检查时的误吸风险

Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-05-15

基于全国商业理赔数据库的回顾性队列研究纳入2005至2021年6,806,046例次门诊上消化道内镜,比较胰高血糖素样肽-1受体激动剂(GLP1-RA)、二肽基肽酶4抑制剂(DPP4i)与慢性阿片类使用者术后14天内误吸及肺部不良事件。GLP1-RA与DPP4i相比各结局粗相对风险均未升高,与阿片类相比肺炎和呼吸衰竭风险更低。结论认为2型糖尿病患者使用GLP1-RA不增加上消化道内镜后肺部并发症风险。

要点

  • 上消化道内镜后肺部不良事件罕见,约每1万例次6至25例。
  • GLP1-RA与DPP4i相比,误吸、误吸性肺炎、肺炎、呼吸衰竭粗相对风险均未升高。
  • GLP1-RA与慢性阿片类相比,肺炎和呼吸衰竭粗相对风险更低。

核心结论

  • 在2型糖尿病患者中,与DPP4i相比,使用GLP1-RA不增加上消化道内镜后肺部并发症风险。

研究设计与样本

  • 利用全国商业行政理赔数据库开展的回顾性队列研究,纳入2005至2021年18至64岁接受门诊上消化道内镜的2型糖尿病患者。
  • 共识别6,806,046例次上消化道内镜操作。
  • 比较GLP1-RA、DPP4i与慢性阿片类使用者内镜后14天内的误吸及相关肺部不良事件理赔。
  • 对年龄、性别、Charlson合并症评分、基础呼吸系统疾病及胃轻瘫进行了校正。

主要发现

  • 上消化道内镜后肺部不良事件罕见,为每1万例次操作6至25例。
  • GLP1-RA与DPP4i相比,误吸粗相对风险0.67(95%CI 0.25-1.75),误吸性肺炎0.95(95%CI 0.40-2.29),肺炎1.07(95%CI 0.62-1.86),呼吸衰竭0.75(95%CI 0.38-1.48),均未升高。
  • GLP1-RA与阿片类相比,误吸粗相对风险0.42(95%CI 0.15-1.16),误吸性肺炎0.60(95%CI 0.24-1.52),肺炎0.30(95%CI 0.19-0.49),呼吸衰竭0.24(95%CI 0.13-0.45)。
  • 上述结果在多项敏感性分析中保持一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Glucagon-like peptide-1-receptor agonists (GLP1-RAs) have been associated with greater retention of gastric contents, however, there is minimal controlled, population-based data evaluating the potential adverse effects of GLP1-RA in the periprocedural setting. We aimed to determine if there is increased risk of aspiration and aspiration-related complications after upper endoscopy in patients using GLP1-RAs. METHODS: We used a nationwide commercial administrative claims database to conduct a retrospective cohort study of patients aged 18 to 64 with type 2 diabetes who underwent outpatient upper endoscopy from 2005 to 2021. We identified 6,806,046 unique upper endoscopy procedures. We compared claims for aspiration and associated pulmonary adverse events in the 14 days after upper endoscopy between users of GLP1-RAs, dipeptidyl peptidase 4 inhibitors (DPP4is), and chronic opioids. We adjusted for age, sex, Charlson Comorbidity score, underlying respiratory disease, and gastroparesis. RESULTS: We found that pulmonary adverse events after upper endoscopy are rare, ranging from 6 to 25 events per 10,000 procedures. When comparing GLP1-RAs with DPP4i, crude relative risks of aspiration (0.67; 95% CI, 0.25-1.75), aspiration pneumonia (0.95; 95% CI, 0.40-2.29), pneumonia (1.07; 95% CI, 0.62-1.86), or respiratory failure (0.75; 95% CI, 0.38-1.48) were not higher in patients prescribed a GLP1-RA. When comparing GLP1-RAs with opioids, crude relative risks were 0.42 (95% CI, 0.15-1.16) for aspiration, 0.60 (95% CI, 0.24-1.52) for aspiration pneumonia, 0.30 (95% CI, 0.19-0.49) for pneumonia, and 0.24 (95% CI, 0.13-0.45) for respiratory failure. These results were consistent across several sensitivity analyses. CONCLUSIONS: GLP1-RA use is not associated with an increased risk of pulmonary complications after upper endoscopy compared with DPP4i use in patients with type 2 diabetes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Barlowe TS, Anderson C, Sandler RS, et al. Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes. Clin Gastroenterol Hepatol. 2024. PMID: 38759826. doi:10.1016/j.cgh.2024.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。